Bristol-Myers Squibb Co (BMYMP.PK) Quote| Reuters.com
Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

1,231.90USD
6 Jun 2016
Change (% chg)

-- (--)
Prev Close
$1,231.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17
52-wk High
$1,231.90
52-wk Low
$991.88

BMYMP.PK

Chart for BMYMP.PK

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from... (more)

Overall

Beta: 0.50
Market Cap(Mil.): $122,777.50
Shares Outstanding(Mil.): 1,669.31
Dividend: 0.38
Yield (%): 2.07

Financials

  BMYMP.PK Industry Sector
P/E (TTM): 78.57 35.27 36.15
EPS (TTM): 0.94 -- --
ROI: 6.57 15.09 14.31
ROE: 10.52 16.14 15.51

Circuit revives Bristol-Myers lawsuit over AIDS drug distribution deal

A federal appeals court revived a lawsuit by Bristol-Myers Squibb Co accusing Indian generic drug maker Mylan Laboratories Ltd of breaching an agreement to distribute a generic version of an AIDS drug in developing countries.

8:53am EDT

BRIEF-Bristol-Myers Squibb, Psioxus Therapeutics announce immuno-oncology clinical collaboration

* Bristol-Myers squibb and psioxus therapeutics announce immuno-oncology clinical collaboration to evaluate the combination of opdivo and enadenotucirev

Jun 30 2016

BRIEF-Bristol-Myers Squibb's Opdivo gets breakthrough therapy approval from FDA

* Bristol Myers Squibb Co - intends to file marketing application with health authorities based on results from phase 2 study ca209-275, other data

Jun 27 2016

BRIEF-PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb's first collaboration product candidate

* Says it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS)

Jun 15 2016

BRIEF-Bristol-Myers announces phase 2 data for Opdivo studies

* Says Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients

Jun 10 2016

BRIEF-Bristol-Myers Squibb announces new rheumatoid arthritis research

* Announces new rheumatoid arthritis research and real-world data at the annual European Congress Of Rheumatology (EULAR 2016) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 08 2016

BRIEF-Bristol-Myers Squibb declares qtrly dividend of $0.38/shr

* Declared a quarterly dividend of $0.38 per share on $0.10 par value common stock of corporation Source text for Eikon: Further company coverage:

Jun 07 2016

BRIEF-Bristol-Myers Squibb, MD Anderson announce new collaboration focused on lung cancer

* Bristol-Myers Squibb and MD Anderson announce new research collaboration in immuno-oncology focused on lung cancer

Jun 07 2016

BRIEF-Bristol-Myers Squibb posts data from trials evaluating Opdivo, Yervoy regimen

* Bristol-Myers Squibb -long-term data from two trials evaluating opdivo and yervoy regimen in advanced melanoma continues to validate co's immuno-oncology combination approach Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 06 2016

Case to Watch: California to weigh jurisdiction for out-of-state plaintiffs

The California Supreme Court is set to decide whether non- residents can sue pharmaceutical giant Bristol-Myers Squibb in its state courts, in an appeal that could clarify what presence companies must have in California in order to be sued there by out-of-state plaintiffs.

May 31 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $121.27 -0.03
Pfizer Inc. (PFE.N) $35.59 +0.38
Merck & Co., Inc. (MRK.N) $57.88 +0.28
Sanofi SA (SASY.PA) €75.02 +0.10
AstraZeneca plc (AZN.L) 4,502.50p +35.50
GlaxoSmithKline plc (GSK.L) 1,600.00p -4.50
Eli Lilly and Co (LLY.N) $78.79 +0.04
Roche Holding Ltd. (ROG.S) CHF256.70 +0.60
Roche Holding Ltd. (RO.S) CHF260.00 +1.75

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.